Cognito Therapeutics Raises $105M Series C to Advance Spectris Neurotechnology for Alzheimer’s

The funding round was led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation from Apollo Health Ventures, Benvolio Group, New Vintage and other investors.

Cognito Therapeutics has raised $105 million in an oversubscribed Series C funding round to advance development of its Spectris neurotechnology platform designed to treat Alzheimer’s disease using non-invasive sensory stimulation.

The funding round was led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation from Apollo Health Ventures, Benvolio Group, New Vintage and other investors.

The Massachusetts-based company develops therapies that use synchronized visual and auditory stimulation to target neural activity associated with neurodegenerative disorders. Its investigational platform, Spectris, is prescribed by physicians and used by patients at home to stimulate neural networks through natural sensory pathways. The approach aims to evoke coordinated neural activity across interconnected brain networks with the goal of improving cognition and daily functioning in Alzheimer’s patients.

Cognito said the latest funding will be used to advance the pivotal HOPE study evaluating Spectris AD Therapy for the treatment of Alzheimer’s disease. The trial is currently fully enrolled, with data readout expected later this year.

The company also plans to use the capital to prepare for regulatory submission to the US Food and Drug Administration, continue clinical development of the Spectris platform and support anticipated commercialization of the technology in 2027.

Beyond Alzheimer’s disease, Cognito intends to expand the Spectris platform into additional neurodegenerative indications through collaborations, including work with the WVU Rockefeller Neuroscience Institute.

Gerald Chan, founder of Morningside Ventures and chairman of Cognito’s board, said the platform combines neuroscience research with engineering and clinical development to address neurodegenerative conditions. “Spectris has the potential to redefine how a broad category of neurodegenerative diseases are treated by moving therapy into the home and reducing the burden on patients and caregivers,” he said in a statement.

The company has been expanding its research ecosystem in recent years. In 2025, Cognito launched the Brain Health Collaboratory with the WVU Rockefeller Neuroscience Institute to accelerate research and validation of non-drug neurotherapies.

Cognito has previously secured multiple funding rounds to support development of its technology. In 2023, the company raised $73 million in Series B financing, bringing its total funding at the time to $93 million. Earlier studies reported that its gamma sensory stimulation approach reduced white matter atrophy in patients with Alzheimer’s disease.

The company received Breakthrough Device Designation from the US Food and Drug Administration in 2021 for its non-invasive neurostimulation device.

Stay tuned for more such updates on Digital Health News